Clinical utility gene card for: multiple endocrine neoplasia type 2.

Eur J Hum Genet

Endocrine Practice and Molecular Laboratory, Heidelberg, Germany.

Published: January 2012

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234510PMC
http://dx.doi.org/10.1038/ejhg.2011.142DOI Listing

Publication Analysis

Top Keywords

clinical utility
4
utility gene
4
gene card
4
card multiple
4
multiple endocrine
4
endocrine neoplasia
4
neoplasia type
4
clinical
1
gene
1
card
1

Similar Publications

Background: Patients with a left ventricular ejection fraction ≤ 35% are at increased risk of sudden cardiac death (SCD) within the first months after a myocardial infarction (MI). The wearable cardioverter defibrillator (WCD) is an established, safe and effective solution which can protect patients from SCD during the first months after an MI, when the risk of SCD is at its peak. This study aimed to evaluate the cost-effectiveness of WCD combined with guideline-directed medical therapy (GDMT) compared to GDMT alone, after MI in the English National Health Service (NHS).

View Article and Find Full Text PDF

Purpose: To compare the efficac and safety of a dual-blade 20,000 cuts per minute (cpm) vitrectomy probe with a single-blade 10,000 cpm probe for primary rhegmatogenous retinal detachment (RRD).

Study Design: Prospective, randomized controlled clinical trial.

Methods: Evaluations were conducted preoperatively, intraoperatively, and at three months postoperatively.

View Article and Find Full Text PDF

Immune checkpoint inhibitors have improved the treatment of metastatic renal cell carcinoma (RCC), with the combination of nivolumab (NIVO) and ipilimumab (IPI) showing promising results. However, not all patients benefit from these therapies, emphasizing the need for reliable, easily assessable biomarkers. This multicenter study involved 116 advanced RCC patients treated with NIVO + IPI across nine oncology centers in Poland.

View Article and Find Full Text PDF

Background: T cells are involved in every stage of tumor development and significantly influence the tumor microenvironment (TME). Our objective was to assess T-cell marker gene expression profiles, develop a predictive risk model for human papilloma virus (HPV)-negative oral squamous cell carcinoma (OSCC) utilizing these genes, and examine the correlation between the risk score and the immunotherapy response.

Methods: We acquired scRNA-seq data for HPV-negative OSCC from the GEO datasets.

View Article and Find Full Text PDF

Objective: In advanced ovarian cancer, the majority of patients receive anti-angiogenic treatment with bevacizumab. However, its use is often associated with severe side effects, and not all patients benefit from the therapy. Currently, there are no reliable biomarkers to predict response to treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!